McKesson

Alexion adds Orloff, Law and Franchini to leadership team

Monday, June 5, 2017

Alexion Pharmaceuticals announced key additions to its executive leadership team. Reporting to Chief Executive Officer Ludwig Hantson will be: John Orloff, M.D., executive vice president, head of Research & Development; Anne-Marie Law, executive vice president, chief human resources officer; and Indrani Lall Franchini, J.D., executive vice president, chief compliance officer.

[Read More]

Southern Cancer Center joins The US Oncology Network

Thursday, February 2, 2017

Southern Cancer Center, a physician-owned multi-site medical oncology practice serving the Alabama Gulf Coast region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for independent practices such as Southern Cancer Center navigating today’s challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry provider of solutions that empower the community patient care delivery system to advance the science, technology and quality of care. Southern Cancer Center and The US Oncology Network share a vision of keeping independent physician groups strong and viable, while aiming to improve patient health.

[Read More]

Woodlands Medical Specialists joins The US Oncology Network

Thursday, September 8, 2016

Woodlands Medical Specialists, a physician-owned multi-specialty outpatient clinic serving Florida’s Panhandle region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for large practices such as Woodlands navigating today’s challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care. The agreement unites two like-minded organizations with a vision of keeping independent physician groups strong and viable, while sharing a common goal of improving patient health.

[Read More]

McKesson acquires Celesio

Friday, January 24, 2014

McKesson, a North American healthcare services and information technology company, has reached an agreement with Franz Haniel to acquire its entire holding of Celesio shares for $32.24 per share. In a separate and subsequent agreement, McKesson announced the acquisition of Celesio convertible bonds from Elliott. These agreements are not subject to any closing conditions and the transactions are expected to close within 10 business days. After the close of the agreements, McKesson will own more than 75% of Celesio shares on a fully diluted basis.

[Read More]

McKesson to acquire Celesio for $8.3 billion

Monday, October 28, 2013

McKesson, a North American healthcare services and information technology company, has signed an agreement to acquire a majority stake in Celesio, an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, for $32 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio. The offer price represents a 39% premium over the three-month volume weighted average price prior to the market speculation that began Oct. 8. The total transaction, including the assumption of Celesio’s outstanding debt, is valued at approximately $8.3 billion.

[Read More]

Quintiles undertakes genomic “pre-profiling” feasibility study

Friday, September 27, 2013

CRO Quintiles has announced plans to improve the development of biomarker-targeted therapies through a novel approach that promotes the genomic “pre-profiling” of cancer patients. Quintiles is undertaking a study with the participation of U.S. Oncology Research, supported by McKesson Specialty Health and The U.S. Oncology Network, to explore the operational feasibility and clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC) patients. The study will investigate how pre-profiling and genomic sequencing data may support physician treatment decisions, including the identification of appropriate clinical trials for patients.

[Read More]